Verrica Pharmaceuticals (DE:1NE0)
NASDAQ:1NE0
1NE0 Stock Chart & Stats
€5.17
--
Market closed
€5.17
--
Day’s Range― - ―
52-Week Range€2.78 - €8.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)20.00
Market Cap
€85.95M
Enterprise Value€44.75M
Total Cash (Recent Filing)€20.60M
Total Debt (Recent Filing)€1.44M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Aug 11, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding17,178,785
10 Day Avg. Volume0
30 Day Avg. Volume20
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)3.58
Price to Sales (P/S)2.49
P/FCF Ratio-5.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.87Price Target Upside168.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.36
Revenue Forecast (FY)€21.94M
Bulls Say, Bears Say
Bulls Say
Robust Revenue And Unit GrowthSustained double‑digit revenue and very strong unit growth indicate accelerating provider adoption and real end‑market demand. Durable uptake across prescribers supports scaling of sales operations, increases predictability of recurring product sales, and forms a foundation for margin expansion as fixed commercial costs are leveraged.
Very High Product Gross MarginsVery high gross margins imply strong product economics and pricing power, enabling the company to absorb elevated SG&A/R&D while preserving the path to profitability as sales scale. Durable product‑level margins provide leverage for reinvestment, better cash conversion, and resilience to moderate cost inflation or distribution markups.
International Partner Funding And Japan LaunchPartner launch and material trial funding shift development cost and commercial risk away from Verrica, accelerating global expansion while preserving cash. This structural support de‑risks Phase III spend, enables earlier market access in Japan, and creates a scalable international revenue avenue tied to partner commercialization capabilities.
Bears Say
Material Cash Burn With Limited RunwayA runway into roughly one year creates a near‑term financing imperative that constrains strategic flexibility. Continued cash burn means reliance on external capital, raising dilution or covenant risks and potentially forcing tradeoffs between commercial investments and development priorities if new funding terms are unfavorable.
Persistent Net Losses And Rising OPEXOperating losses combined with rising R&D and commercial spend keep the company materially unprofitable. If revenue growth slows, elevated opex will delay durable profitability and amplify refinancing needs, limiting ability to self‑fund pipeline progression and commercial roll‑out without dilutive capital or partner arrangements.
Adoption And Access Challenges (pediatrics/PBMs)Long‑term upside depends on changing clinical behavior and securing PBM/pediatric coverage. Slow conversion from watch‑and‑wait and gross‑to‑net variability can cap realized sales and delay penetration into the largest pediatric cohorts, making revenue growth and margin stability contingent on durable access improvements.
Verrica Pharmaceuticals News
1NE0 FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was €2.78 and its highest was €8.80 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Verrica Pharmaceuticals’s market cap is €85.95M.
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is Aug 11, 2026 which is in 55 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on May 12, 2026. The company reported -€0.39 earnings per share for the quarter, missing the consensus estimate of -€0.364 by -€0.026.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -0.35.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 17,178,785 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of -€0.39 in its last earnings report, missing expectations of -€0.364. Following the earnings report the stock price went up 4.723%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:1NE0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Verrica Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€13.87 (168.18% Upside)
€13.87 (168.18% Upside)
Blogger Sentiment
Bullish
DE:1NE0 Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.75%
12-Months-Change
Fundamentals
Return on Equity
-1136.50%
Trailing 12-Months
Asset Growth
-8.04%
Trailing 12-Months
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc. is a US-based pharmaceutical company dedicated to developing and commercializing therapeutic solutions for various skin diseases. Its primary investigational compound, VP-102, has successfully completed Phase II clinical trials for molluscum contagiosum and external genital warts, and is presently in Phase II development for common warts. Additionally, the company is advancing VP-103, a cantharidin-based product candidate, designed to treat plantar warts. Verrica maintains a strategic license and collaboration agreement with Torii Pharmaceutical Co., Ltd., focusing on the development and commercialization of its product candidates, including VP-102, for molluscum contagiosum and common warts in the Japanese market. Furthermore, a separate licensing agreement with Lytix Biopharma AS allows for the development and commercialization of LTX-315 for dermatological oncology applications. Verrica Pharmaceuticals Inc. was established in 2013 and has its headquarters in West Chester, Pennsylvania.
1NE0 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum for YCANTH — notably large year-over-year unit growth (51.3%), record monthly dispensing, a Japan launch and an advancing global Phase III program — and compelling Phase II clinical data for VP-315 (97% objective response, 86% tumor size reduction). These positive operational, regulatory and clinical developments are tempered by near-term financial pressures: a Q1 net loss, increased R&D and SG&A spend, modest gross-to-net variability, remaining access work particularly in pediatrics/PBMs, and a cash runway into Q1 2027 that implies a forthcoming financing need. Overall, the progress on product adoption, pipeline advancement, and international expansion outweigh the financial and access challenges reported.View all DE:1NE0 earnings summaries1NE0 Stock 12 Month Forecast
Average Price Target
€13.87
▲(168.18% Upside)
Technical Analysis
Options Prices
Currently, No data available
---